T16523L |
PhiKan 083
|
880813-36-5
|
98.2%
|
|
PhiKan 083 is a carbazole derivative
|
T6585 |
SAR405838
|
1303607-60-4
|
98.04%
|
|
MI-773 (SAR405838 (MI 773)) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
|
T16771 |
RO-5963
|
1416663-77-8
|
98%
|
|
RO-5963 is a dual inhibitor of p53-MDM2 and p53-MDMX (IC50s: ~17 nM and ~24 nM, respectively).
|
T28509 |
RDR03871
|
286008-51-3
|
97.78%
|
|
RDR03871 is an MDM2 inhibitor.
|
T1798 |
RITA
|
213261-59-7
|
97.76%
|
|
RITA (NSC-652287)(NSC-652287) induced cross-links of both DNA-DNA and DNA-protein with no detectable DNA single-strand breaks. RITA, like nutlin-3, can disrupt t...
|
T3653 |
MX69
|
1005264-47-0
|
97.27%
|
|
MX69 is the MDM2/XIAP inhibitor, blocking the MDM2 protein-XIAP RNA interaction, leading to MDM2 degradation.
|
T2243 |
Serdemetan
|
881202-45-5
|
97.13%
|
|
Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
|
T21578 |
NSC 66811
|
6964-62-1
|
96.94%
|
|
NSC 66811is a novel inhibitor of the murine double minute 2 (MDM2)-p53 interaction. It binds to MDM2 with a Ki of 120 nM and activates p53 in cancer cells with a...
|
T11980 |
MD-224
|
2136247-12-4
|
100%
|
|
MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.
|
T12040 |
Milademetan
|
1398568-47-2
|
100%
|
|
Milademetan (DS-3032) is an orally active and potent MDM2 inhibitor with antitumor activity that induces G1 cell cycle arrest, senescence, and apoptosis.Milademe...
|
T3184 |
Kevetrin hydrochloride
|
66592-89-0
|
98%
|
|
Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride) is a small molecule and activator of the tumor suppressor protein p53, with potential antineo...
|
T6965 |
RG7112
|
939981-39-2
|
98%
|
|
RG7112 (RO5045337) (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
|
T9698 |
UC2288
|
1394011-91-6
|
98%
|
|
UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein sta...
|